What the fda wantsThe briefing documents AND the adcom members commentary all came to the same conclusion: the clinical results are interesting but we need a proof that they are link to mcna and not simply the results of prior bcg instillation.
How can they answer that question without allowing clinical trial on bcg naive patient? Is it possible to do that?
i bought most of my stock pre adcom, and that was a lot. Very rough day